Geno's unit: KAM based, small team with large geography for Pfizer FTEs. Largest medical presence-RMRS, IORS, etc. No CSO. Amy's unit: the largest force, but only limited numbers will be Pfizer FTEs. Bulk converted to CSO including the entirety of vaccines & consumer. Only Onc will be FTE. Most PC KAMs will transfer into this unit as PFE FTEs. The pull through efforts (field reps) will be CSO in the $50k-year range. John's unit: Contract driven. 10-12 national account managers for the entire division. Nothing else. Period. Will be sold as soon as legacy costs are RIFed. ELT Pay: will continue to rise due not to revenue or organic profit growth but due to painful cost cutting measures born by you smucks in the field.
Geno's BU will be specialty and PC. Specialty is already larger territories with fewer reps., PC will remain in-tact except for the drugs that have LOE of 2015 or sooner. Will experience field force reductions as needed. The BU will not be primarily KAM based as OP is trying to pass off, but may expand KAM size based on some delusional idea that a KAM provides value, even though they are useless. All the BU's will still have the MOS as a support team. Amy's BU will be Onc., and Vaccines which will remain intact, except for potential reduction in vaccine based on ACIP future rec's. MOS's in this BU will remain in tact for their divisions. Consumer is just placed here because it is currently under Amy's control. John's BU of Established products is primarily contract based due to the generic nature of the BU. LOE drugs will have sales force need or CSO becomes an option. There is no upside in the generics BU, which should be obvious unless there is a planned change in the structure of this BU. Likely to be sold as previously indicated by CEO, but not before 2016. The OP's is not very well informed on BU structure so they don't know what they are talking about with the exception that it is up in the air how the company will see a CSO structure in their future.
How does PC C1 stay in tact if they lose Celebrex? That's the mystery as Celebrex moves to Value. However will C1 still promote it?
Any word on Cluster 4 for Pristiq since it has been placed in the Generic Bag? i.e. Will Cluster 4 be eliminated?
Contract sales takes:Tovias AZ: Pristiq before LOE C1 - 2 get consolidated: Lyrica, Elliquis, Chantix. C4 Lyrica territories stay intact Large specialist (DSR) territories stay intact calling on Neuros or Cardiologists. Inline territories: Elliquis=10 targets Chantix= promoted 2 months out of the year Lyrica= year round No more c1 & c2
